ScreenerHero

SNTI Senti Biosciences Holdings, Inc.

NAS · US · Healthcare · Biotechnology · sentibio.com
0.3300USD+2.17%Mkt Cap: 10.28M $P/E: —

Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap10.28M USD
Enterprise Value23.68M USD
Revenue (TTM)55.00K USD
Gross Profit-31.27M USD
Net Income (TTM)-61.44M USD
Revenue/Share0.0020 USD
Last Price0.3300 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees39
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.34
PEG—
EV/EBITDA-0.47
EV/Revenue430.52
P/S182.91
P/B-2.96
EPS (TTM)-1.56
EPS (Forward)-0.95
52W Range
0.29002% of range2.880
52W High2.880 USD
52W Low0.2900 USD
Profitability
Gross Margin0.00%
Oper. Margin-79370.59%
EBITDA Margin0.00%
Profit Margin-279263.64%
ROE-1099.27%
ROA-119.94%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-43.44M USD
CapEx (TTM)196.00K USD
FCF Margin-31113.41%
FCF Yield-166.50%
Net Debt13.62M USD
Net Debt/EBITDA-0.27
Balance Sheet
Debt/Equity5.17
Current Ratio0.82
Quick Ratio0.45
Book Value/Sh-0.11 USD
Cash/Share0.21 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateJul 18, 2024
Analyst Consensus
Rating—
Target (Mean)13.50 USD
Upside (mean)+3990.9%
Target Range12.00 USD – 15.00 USD
12.00+3990.9% to mean15.00
# Analysts2
Ownership
Shares Out.31.15M
Float12.28M
Insiders48.43%
Institutions19.03%
Short Interest
Short Ratio2.6d
Short % Float2.94%
Short % Out.1.64%
Shares Short510.82K
Short (prev mo.)519.65K
Technical
SMA 500.3535 (-6.6%)
SMA 2000.8077 (-59.1%)
Beta2.22
S&P 52W Chg16.45%
Avg Vol (30d)568.23K
Avg Vol (10d)1.58M
Technical Indicators
RSI (14)45.0
MACD-0.0199
MACD Signal-0.0290
MACD Hist.+0.0091
BB Upper0.3476 USD
BB Middle0.3188 USD
BB Lower0.2900 USD
BB Width18.06%
ATR (14)0.0342 USD
Vol Ratio (20d)0.43x